Espinoza Octavio — SEC Form 4 filings
SEC reporting owner CIK 1905248. 24 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2024-02-16 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 1,500 shares, $156,090 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 24 legs across 9 filings — 71,737 shares, $15,143,193 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 79.
- Largest priced transaction: sale of 31,641 shares @ $292.06 ($9,241,229) in LIGAND PHARMACEUTICALS INC, filed 2026-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC (LGND) | Chief Financial Officer | 24 | 2 legs · 1,500 sh · $156,090 | 24 legs · 71,737 sh · $15,143,193 | 79 |
Form 4 filings — Espinoza Octavio
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 16,179 @ $52.84 · Option exercise (M): 2,074 @ $70.04 · Option exercise (M): 2,869 @ $55.75 · Option exercise (M): 7,171 @ $57.22 · Option exercise (M): 3,348 @ $68.74 · Sale (S): 31,641 @ $292.06 · +5 more | EDGAR |
| 2026-07-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 17 @ $160.71 | EDGAR |
| 2026-05-28 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 764 @ $63.62 · Option exercise (M): 972 @ $52.84 · Option exercise (M): 972 (derivative) @ $0 · Option exercise (M): 764 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 4,933 @ $0 · Grant/award (A): 23,527 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 2,405 @ $92.65 · Sale (S): 3,057 @ $225 · Option exercise (M): 2,405 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 1,607 @ $58.49 · Option exercise (M): 466 @ $80.72 · Sale (S): 699 @ $198.71 · Sale (S): 53 @ $200.08 · Sale (S): 698 @ $201.09 · Sale (S): 950 @ $201.73 · +9 more | EDGAR |
| 2026-02-18 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 7,390 @ $0 · Tax withholding (F): 3,761 @ $183.83 · Grant/award (A): 8,810 @ $0 · Tax withholding (F): 4,483 @ $183.83 · Tax withholding (F): 1,026 @ $183.83 · Tax withholding (F): 1,223 @ $183.83 · +1 more | EDGAR |
| 2026-01-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 8 @ $95.68 | EDGAR |
| 2025-12-18 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 1,194 @ $52.84 · Option exercise (M): 69 @ $57.22 · Option exercise (M): 285 @ $63.62 · Option exercise (M): 652 @ $92.65 · Option exercise (M): 181 @ $103.42 · Option exercise (M): 1,194 (derivative) @ $0 · +4 more | EDGAR |
| 2025-12-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 1,804 @ $188.31 | EDGAR |
| 2025-12-09 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 1,862 @ $184.87 | EDGAR |
| 2025-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 224 @ $91.08 | EDGAR |
| 2025-05-13 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Purchase (P): 1,000 @ $103.89 · Purchase (P): 500 @ $104.40 | EDGAR |
| 2025-03-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 5,000 @ $115.03 · Grant/award (A): 7,484 @ $0 · Grant/award (A): 32,717 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 5,429 @ $0 · Tax withholding (F): 2,757 @ $120 · Grant/award (A): 7,390 @ $0 · Tax withholding (F): 3,803 @ $120 · Tax withholding (F): 1,024 @ $120 · Tax withholding (F): 782 @ $120 · +1 more | EDGAR |
| 2024-12-26 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 2,104 @ $116.37 | EDGAR |
| 2024-12-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 1,859 @ $123.51 | EDGAR |
| 2024-09-24 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 200 @ $103.98 · Sale (S): 275 @ $103.86 · Sale (S): 800 @ $103.95 | EDGAR |
| 2024-09-19 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 1,417 @ $80.72 · Option exercise (M): 69 @ $57.22 · Option exercise (M): 69 (derivative) @ $0 · Option exercise (M): 1,417 (derivative) @ $0 | EDGAR |
| 2024-08-30 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 207 @ $57.22 · Option exercise (M): 546 @ $70.04 · Option exercise (M): 207 (derivative) @ $0 · Option exercise (M): 546 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 267 @ $60.71 | EDGAR |
| 2024-05-17 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 5,873 @ $86.01 · Sale (S): 2,264 @ $86.00 · Option exercise (M): 206 @ $57.22 · Option exercise (M): 1,544 @ $63.62 · Option exercise (M): 145 @ $68.74 · Option exercise (M): 5,022 @ $52.84 · +6 more | EDGAR |
| 2024-02-29 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 7,208 @ $0 · Option exercise (M): 799 @ $55.75 · Option exercise (M): 140 @ $57.22 · Option exercise (M): 325 @ $58.49 · Sale (S): 140 @ $88.46 · Option exercise (M): 799 (derivative) @ $0 · +3 more | EDGAR |
| 2024-02-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 1,479 @ $74.65 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1905248 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →